ALK and osteosarcoma: Osteosarcoma samples zccs225 and zccs265 were generally sensitive to dactinomycin, dinaciclib (CDK1/2/5/9 inhibitor), carfilzomib (proteasome inhibitor) and ceritinib (ALK inhibitor) (Figs. 6B and EV5D).